Clinical Trial Finder

Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics

Study Purpose

The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Observational
Eligible Ages 3 Years - 80 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients who are regularly visited and followed up in the appropriate patient; department.
  • - All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases: - coronary artery disease group; - arrhythmia group; - heart valve disease group; - aortic dissection group; - cardiac masses group; - myocarditis group; - hypertension group; - cardiomyopathy group; - structural heart disease group; - ischemic cerebrovascular disease group; - hemorrhagic cerebrovascular disease group; - intracranial space occupying lesion group.

Exclusion Criteria:

  • - Age <3 years or >80 years old; - Pregnant and lactating women; - The patient declined to provide informed consent to participate in the study; - None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead.
Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT06001073
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 First Affiliated Hospital Xi'an Jiaotong University
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 Gouliang LiYang Yan
Principal Investigator Affiliation First Affiliated Hospital Xi'an Jiaotong UniversityFirst Affiliated Hospital of Xian Jiaotong University
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 Other
Overall Status Not yet recruiting
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Coronary Artery Disease, Arrhythmias, Cardiac, Heart Valve Diseases, Aortic Dissection, Heart Neoplasms, Myocarditis, Hypertension, Cardiomyopathies, Structural Heart Disease, Ischemic Cerebrovascular Disease, Hemorrhagic Cerebrovascular Disease, Brain Neoplasms
Additional Details

Cardiovascular and cerebrovascular diseases refer to ischemic and hemorrhagic diseases of the heart, brain and body tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc. It is one of the major public health problems in the world. The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.

Arms & Interventions

Arms

: Coronary artery disease group

Diagnosis of coronary artery disease by clinical guidelines.

: Arrhythmia group

Diagnosis of arrhythmia by clinical guidelines. by clinical guidelines.

: Heart valve disease group

Diagnosis of heart valve disease by clinical guidelines.

: aortic dissection group

Diagnosis of aortic dissection by clinical guidelines.

: Cardiac masses group

Diagnosis of cardiac messes by clinical guidelines.

: Myocarditis group

Diagnosis of myocarditis by clinical guidelines.

: Hypertension group

Diagnosis of hypertension by clinical guidelines.

: Cardiomyopathy group

Diagnosis of cardiomyopathy by clinical guidelines.

: Structural heart disease group

Diagnosis of structural heart disease by clinical guidelines.

: Ischemic cerebrovascular disease group

Diagnosis of ischemic cerebrovascular disease by clinical guidelines.

: Hemorrhagic cerebrovascular disease group

Diagnosis of hemorrhagic cerebrovascular disease by clinical guidelines.

: Intracranial space occupying lesion group

Diagnosis of intracranial space occupying by clinical guidelines.

Interventions

Other: - Observational; No Interventions were given.

Observational; No Interventions were given.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Xi'an, Shaanxi, China

Status

Address

First Affiliated Hospital of Xian Jiantong University

Xi'an, Shaanxi, 710061

Powered By

Stay Informed & Connected